Novo Nordisk has terminated a marketing partnership with telehealth company Hims & Hers Health after only eight weeks, alleging unlawful mass distribution of compounded versions of the obesity drug Wegovy. The partnership had been designed to transition patients from compounded formulations provided under emergency drug shortage provisions back to branded Wegovy. Novo cited patient safety concerns related to unregulated foreign active pharmaceutical ingredients. Hims disputes the claims, and the controversy triggered a near 30% share price drop for the telehealth firm. This move underscores ongoing challenges in meeting demand and regulatory compliance in the obesity therapy market.